Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer
- 4 February 2015
- journal article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 47 (3) , 473-477
Abstract
To investigate the diagnostic value of the nuclear matrix protein 22 (NMP-22) in residual tumors after complete transurethral resection (TUR) of bladder cancer. A total of 160 patients diagnosed with non-muscle invasive bladder cancer were prospectively enrolled in the study. Before the initial TUR, the patients were evaluated using urine cytology and the NMP-22 Bladder Chek™. After 4–6 weeks, all patients underwent a second TUR, urine cytology and NMP-22 Bladder Chek™ evaluation. The mean patient age was 59.8 ± 1.0 years. Of the 160 patients, 81 (50.6 %) had positive NMP-22 findings and 53 (33.1 %) had positive urine cytology findings. In 101 (63.1 %) patients, at least one marker was positive. There was no correlation between the positivity ratio of the NMP-22 and the degree of risk group (p = 0.156); however, in the high-risk group, the malignant cytology ratio was higher (p < 0.001). In 60 patients (37.5 %), there were tumors in the second TUR. NMP-22 results of 40 of these patients (66.7 %) were positive, and for 28 (46.7 %), the cytology results were positive. The sensitivity, specificity, positive predictive value, and negative predictive value of the NMP-22 alone was 66.7, 81, 67.8, and 80.2 %, respectively; for the cytology, it was 46.7, 98, 93.3, and 75.4 %, respectively; and for the NMP-22 and cytology combined, it was 73.3, 79, 67.7, and 83.2 %, respectively. NMP-22 Bladder Chek™ test has limited efficacy in detecting residual tumors before a second TUR. The combination of this test with cytology has no additional benefit.Keywords
This publication has 11 references indexed in Scilit:
- Urine markers for detection and surveillance of bladder cancerUrologic Oncology: Seminars and Original Investigations, 2014
- Urinary Markers/CytologyUrologic Clinics of North America, 2013
- Nuclear Matrix Protein 22 as Adjunct to Urine Cytology and Cystoscopy in Follow-up of Superficial TCC of Urinary BladderUrology, 2009
- Urinary Markers in Bladder CancerEuropean Urology, 2008
- Impact of risk factors on the performance of the nuclear matrix protein 22 point‐of‐care test for bladder cancer detectionBJU International, 2008
- Is a Second Transurethral Resection Necessary for Newly Diagnosed pT1 Bladder Cancer?Journal of Urology, 2006
- Urinary NMP22® BladderChek® Test in the Diagnosis of Superficial Bladder CancerEuropean Urology, 2005
- Effect of Routine Repeat Transurethral Resection for Superficial Bladder Cancer: A Long-term Observational StudyJournal of Urology, 2003
- THE VALUE OF A SECOND TRANSURETHRAL RESECTION IN EVALUATING PATIENTS WITH BLADDER TUMORSJournal of Urology, 1999
- The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary BladderAmerican Journal of Surgical Pathology, 1998